Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. (1st June 2013)

• Record Type: Journal Article
• Authors: De Hoffer, Laura; Di Biagio, Antonio; Bruzzone, Bianca; Sticchi, Laura; Prinapori, Roberta; Gerbaldo, Daniela; Gotta, Cristina; Viscoli, Claudio
• Is Part Of: Journal of chemotherapy. Volume 25:Number 3(2013:Jun.)
• Page Start: 181
• Page End: 183
• Publication Date: 2013-06-01
• Subjects: Late presenter -- HIV-1 -- Pregnancy -- Raltegravir -- HIV-RNA decay -- Mother to child transmission; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1179/1973947812Y.0000000066
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : Vertical transmission of human immunodeficiency virus (HIV) represents an important worldwide health problem and rapid decline in viral load is essential for HIV pregnant women to prevent mother to child transmission. Specific issues such as late presentation of pregnant HIV-infected women remain a clinical challenge. We present a case of an HIV-infected woman who presented to our hospital at 35 weeks of pregnancy, who was successfully treated with raltegravir-based first-line combined antiretroviral regimen. Even though there is limited information about safety and tolerability of the use of raltegravir in pregnancy, in our case this drug resulted in a rapid decline in HIV-RNA viral load, without side effects. The aim of the present study and literature review was to demonstrate that raltegravir can be a good treatment choice for very late presenting pregnant women.